Ubs Group Ag Belite Bio, Inc Put Options Transaction History
Ubs Group Ag
- $527 Billion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding BLTE
# of Institutions
22Shares Held
280KCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY168KShares$11.3 Million0.15% of portfolio
-
State Street Corp Boston, MA20KShares$1.35 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC18.3KShares$1.24 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY14.6KShares$987,0510.0% of portfolio
-
Morgan Stanley New York, NY10.6KShares$716,0770.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.68B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...